Current Report Filing (8-k)
November 06 2018 - 8:18AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the
Securities
Exchange Act of 1934
Date
of report (Date of earliest event reported):
November 6, 2018
ONCOSEC
MEDICAL INCORPORATED
(Exact
Name of Registrant as Specified in Charter)
Nevada
|
|
000-54318
|
|
98-0573252
|
(State
or Other Jurisdiction
of
Incorporation)
|
|
(Commission
File
Number)
|
|
(IRS
Employer
Identification
No.)
|
3565
General Atomics Court, Suite 100
San
Diego, California 92121
24
North Main Street
Pennington,
NJ 08534-2218
(Address
of Principal Executive Offices)
(855)
662-6732
(Registrant’s
telephone number, including area code)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
[ ]
|
Written
communications pursuant to Rule 425 under the Securities Act.
|
|
|
[ ]
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act.
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 14d-2b under the Exchange Act.
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act.
|
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company
[ ]
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.[ ]
Item
8.01 Other Events.
On
November 6, 2018, OncoSec Medical Incorporated (the “Company” or “OncoSec”) issued a press release
reporting preliminary data from KEYNOTE-695, a global, multicenter Phase 2b, open-label trial of intratumoral delivery of TAVO™
(tavokinogene telseplasmid / IL-12) with intravenous KEYTRUDA® (pembrolizumab) in patients with unresectable, advanced melanoma.
A copy of the press release is being furnished as Exhibit 99.1 to this report.
On
November 6, 2018, the
Company posted an investor
presentation to its website, www.oncosec.com. A copy of the investor presentation is being furnished as Exhibit 99.2 to this report.
Item
9.01. Financial Statements and Exhibits.
(d)
Exhibits.
The
following exhibits are furnished herewith:
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed
on its behalf by the undersigned hereunto duly authorized.
|
ONCOSEC
MEDICAL INCORPORATED
|
|
(Registrant)
|
|
|
Date:
November 6, 2018
|
|
|
|
|
|
|
By:
|
/s/
Daniel J. O’Connor
|
|
Name:
|
Daniel
J. O’Connor
|
|
Title:
|
Chief
Executive Officer and President
|
OncoSec Medical (NASDAQ:ONCS)
Historical Stock Chart
From Aug 2024 to Sep 2024
OncoSec Medical (NASDAQ:ONCS)
Historical Stock Chart
From Sep 2023 to Sep 2024